CRISPR Therapeutics reported a $581.6 million net loss in 2025 with revenue of just $3.5 million, while continuing to advance its gene-editing pipeline including the approved CASGEVY therapy and next-generation CAR T cell programs. The company maintains strategic partnerships and expects current funds to support operations for at least 24 months.
CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
The cell therapy manufacturing market is projected to reach $14.01 billion by 2035, with CAR-T therapies dominating at 65% market share. Recent FDA approvals for new CAR-T indications and Japanese regulatory acceleration highlight growing clinical adoption, while research advances include new anti-aging protein platforms and CRISPR-based treatments.
Vertex Pharmaceuticals and CRISPR Therapeutics reported $116 million in full-year 2025 sales for gene-editing therapy Casgevy, with 64 patients receiving infusions and patient initiations nearly tripling compared to 2024.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07506863 |
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07055503 |
Use of the Hemanext One® Hypoxic Red Blood Cell Storage System for Transfusion in Thalassemia Patients |
ENROLLING_BY_INVITATION | |
| NCT06512298 |
Plasticizer Exposure and Its Consequences on Health |
NOT_YET_RECRUITING | |
| NCT06363760 |
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301 |
ENROLLING_BY_INVITATION | |
| NCT06280378 |
Β-Thalassemia Treatment with KL003 Cell Injection |
RECRUITING | PHASE1/PHASE2 |
| NCT06219239 |
Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients |
RECRUITING | NA |
| NCT06146478 |
Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients |
COMPLETED | PHASE3 |
| NCT05991336 |
Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy |
RECRUITING | |
| NCT05860595 |
Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia. |
ACTIVE_NOT_RECRUITING | NA |
| NCT04770779 |
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) |
ACTIVE_NOT_RECRUITING | PHASE3 |
